Abbott Laboratories
105.23USD
-0.2900 (-0.27%)
Analyst Ratings
24 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 4 | 17 | 5 | 0 |
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $1.42▲ | $1.42 | 7 | 10 |
| Next quarter | $1.64▲ | $1.62 | 15 | 0 |
| Current year | $5.52▲ | $5.48 | 5 | 1 |
| Next year | $6.06▲ | $6.06 | 3 | 2 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $1.28 | $1.31 | +0.03 (+2.6%) |
| 2026-03-31 | $1.15 | $1.15 | +0.00 (+0.3%) |
| 2025-12-31 | $1.49 | $1.5 | +0.01 (+0.3%) |
| 2025-09-30 | $1.3 | $1.3 | +0.00 (+0.0%) |
428 ratings from 37 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| TD Cowen | Reiterated | Buy | $135 | Sep 8, 2026 |
| TD Cowen | Maintained | Buy | $115 $135 | Aug 25, 2026 |
| TD Cowen | Maintained | Buy | $115 $135 | Aug 21, 2026 |
| Citigroup | Maintained | Buy | $112 $125 | Aug 14, 2026 |
| Wolfe Research | Upgraded from Peer Perform | Outperform | $130 | Aug 13, 2026 |
| UBS | Maintained | Buy | $135 $125 | Jul 28, 2026 |
| Citigroup | Maintained | Buy | $108 $112 | Jul 17, 2026 |
| Piper Sandler | Reiterated | Overweight | $115 $118 | Jul 17, 2026 |
| JP Morgan | Maintained | Overweight | $110 $120 | Jul 17, 2026 |
| Wells Fargo | Maintained | Overweight | $109 $112 | Jul 17, 2026 |
| TD Cowen | Reiterated | Buy | $115 | Jul 17, 2026 |
| Evercore ISI Group | Maintained | Outperform | $112 $120 | Jul 17, 2026 |
| RBC Capital | Reiterated | Outperform | $130 | Jul 17, 2026 |
| BTIG | Maintained | Buy | $131 $134 | Jul 17, 2026 |
| Evercore ISI Group | Maintained | Outperform | $120 $112 | Jul 6, 2026 |
| Baird | Initiated | Outperform | $121 | Jul 1, 2026 |
| Piper Sandler | Reiterated | Overweight | $115 | Jun 22, 2026 |
| Goldman Sachs | Maintained | Buy | $121 $113 | May 31, 2026 |
| BTIG | Reiterated | Buy | $131 | Apr 27, 2026 |
| Barclays | Maintained | Overweight | $144 $143 | Apr 20, 2026 |
| Piper Sandler | Maintained | Overweight | $135 $115 | Apr 17, 2026 |
| Oppenheimer | Maintained | Outperform | $132 $115 | Apr 17, 2026 |
| RBC Capital | Maintained | Outperform | $135 $130 | Apr 17, 2026 |
| Benchmark | Maintained | Buy | $145 $120 | Apr 17, 2026 |
| Evercore ISI Group | Maintained | Outperform | $134 $120 | Apr 17, 2026 |
84 filings from 28 insiders · 17 buy / 3 sell over 6m
Officers and directors of ABT, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| MCCOY JOHN A. JR.Officer, VICE PRESIDENT AND CONTROLLER | Sell | 27 | $109.54 | $3k | Sep 2, 2026 |
| Boudreau Philip POfficer, EVP AND CFO | Tax | 388 | $110.36 | $43k | Sep 1, 2026 |
| MCCOY JOHN A. JR.Officer, VICE PRESIDENT AND CONTROLLER | Tax | 52 | $110.36 | $6k | Sep 1, 2026 |
| FORD ROBERT B.Chief Executive Officer | Sell | 398.8k | $115.57 | $46.20M | Aug 25, 2026 |
| FORD ROBERT B.Chief Executive Officer | Exercise | 398.8k | $44.40 | $21.55M | Aug 25, 2026 |
| MORRONE LOUIS HOfficer | Sell | 5.8k | $109.83 | $643k | Aug 11, 2026 |
| STRATTON JOHN G.Director | Buy | 2.0k | $86.82 | $174k | May 7, 2026 |
| STARKS DANIEL JDirector | Buy | 10.0k | $92.65 | $927k | Apr 27, 2026 |
| ROMAN MICHAEL FDirector | Grant | 2.3k | — | — | Apr 24, 2026 |
| KUMBIER MICHELLE ADirector | Grant | 2.3k | — | — | Apr 24, 2026 |
| MCKINSTRY NANCYDirector | Grant | 2.3k | — | — | Apr 24, 2026 |
| CONROY KEVIN TDirector | Grant | 2.3k | — | — | Apr 24, 2026 |
| O GRADY MICHAEL GDirector | Grant | 2.3k | — | — | Apr 24, 2026 |
| BLOUNT SALLY EDirector | Grant | 2.3k | — | — | Apr 24, 2026 |
| STRATTON JOHN G.Director | Grant | 2.3k | — | — | Apr 24, 2026 |
| GONZALEZ PATRICIA PAOLADirector | Grant | 2.3k | — | — | Apr 24, 2026 |
| AHUJA NITA M.D.Director | Grant | 2.3k | — | — | Apr 24, 2026 |
| MCDEW DARREN WDirector | Grant | 2.3k | — | — | Apr 24, 2026 |
| BABINEAUX CLAIRE FONTENOTDirector | Grant | 2.3k | — | — | Apr 24, 2026 |
| STARKS DANIEL JDirector | Grant | 2.3k | — | — | Apr 24, 2026 |
No analyst notes on ABT yet.
| Buy2.04 |
| 1 mo ago | 4 | 17 | 6 | 0 | 0 | Buy2.07 |
| 2 mo ago | 4 | 16 | 7 | 0 | 0 | Buy2.11 |
| 3 mo ago | 4 | 17 | 7 | 0 | 0 | Buy2.11 |